Dr. Animesh Saha, Radiation Oncologist
MBBS, MD, DNB (Radiotherapy)
Radiation Oncologist
Dr. Animesh Saha Appointment and Practice Locations
DC Block, Office Tower, Sector 1, City Centre,
Salt Lake, Kolkata
Get Directions
OP Timings
Mon - Sat
10:00 am - 01:00 pm
Fee: 1100
For Appointment
58, Canal Circular Road,
Kankurgachi, Kolkata
Get Directions
OP Timings
On Call
Fee: 1000
- Practice Locations (2)
- Profile
- Patient Reviews
- Q&A
- Media
Specializations
Radiation Oncologist
Qualifications
- MBBS - R G Kar Medical College and Hospital - 2009 - Kolkata
- MD - Radiotherapy - West Bengal State University - 2013 - Kolkata
- DNB - Radiotherapy - National Board of Examinations - 2014 - Kolkata
- Fellow of the Royal College of Radiologists - RCR - 2018 - London
- MNAMS
- CESR - General Medical Council - UK
Experiences
- Specialist Registrar Leeds Cancer Centre - NHS Trust - UK - 2017 - 2018
- Consultant Clinical Oncologist Leeds Cancer Centre - NHS Trust - UK - 2018 - 2019
- Consultant Clinical Oncologist Apollo Multispeciality Hospital - Kankurgachi - 2019 - Currently Working
- Consultant Clinical Oncologist Apollo Clinic - Salt Lake - Currently Working
Registrations
- 64647 West Bengal Medical Council 2009
Awards and Recognitions
- Certificate of Eligibility for Specialist Registration (CESR), UK Awarded by General Medical Council, UK in October - 2019
- Cyclotron Trust Award with Travel Grant to Attend the Education Sessions of PTCOG-58 Conference held in Manchester , United Kingdom
- Having Qualified for the Award of Diplomate of the National Board of Examinations in Radiotherapy at the Examination held in December, 2013; has been Admitted by the Council as Member (MNAMS) of the National Academy of Medical Sciences (India) in the year 2018
- FRCR in Clinical Oncology Awarded by Royal College of Radiologists in April,2018
- Achievements :
- International training fellowship in St James University Hospital (Leeds teaching hospital), UK from March 2017- October 2018.
- Fellowship in Clinical oncology from Tata Medical Center, Kolkata, India from June - 2013 to January - 2017
- He was selected for ESMO preceptorship on Brain tumor held between September 28, 2018-September 29, 2018 in Athens, Greece.
- Hypo-fractionated radiotherapy schedule of 35Gy in 10 Fractions in advanced incurable breast cancer: a prospective Phase I/II study (HYPORT study). He got first prize for poster presentation in controversies in Clinical Oncology, which was held in Kolkata, India in 2016
- Oral Presentation in the Royal College of Radiologists Proffered Paper Session in NCRI Conference 2015, Liverpool, UK; for which He got ‘The Company of Biologists Travel Award’
- ‘Is Daily MVCT Imaging Really required in helical tomotherapy for head and neck cancers? : An analysis of a large dataset of 2858 fractions’. He had presented this research work in AROICON West Bengal chapter 2013 in Kolkata,India.
Memberships
- Indian Medical Association (IMA)
- Association of Radiation Oncologists of India (AROI)
- National Academy of Medical Sciences
- Indian Society of Neuro-Oncology (ISNO)
- European Society of Medical Oncology (ESMO)
- European Society for Radiotherapy & Oncology (ESTRO)
- Indian Society of Oncology (ISO)
- Royal College of Physicians (UK)
Paper Presentations
- A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789)
- Addition of Stereotactic Body Radiotherapy to Systemic Chemotherapy in Locally Advanced Biliary Tract Cancers (ABC07 trial)
- A Randomised Trial of Conventional Care Versus Radioablation (Stereotactic Body Radiotherapy) for Extracranial Oligometastases (CORE trial)
- ETOP/IFCT 4-12 STIMULI Trial which is an Open-label, Randomised, Two-Arm, Phase II trial Looking into Addition of Immunotherapy with Nivolumab and Ipilumumab to Standard of Care in Limited Stage Small Cell Lung Carcinoma
- A Randomized, Phase 3 Trial with Anti-PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) Versus Placebo for Patients with Early Stage NSCLC after Resection and Completion of Standard Adjuvant Therapy (PEARLS)
- GO40241 Phase III Randomized, Double-Blind, Placebo-Controlled Study (Neoadjuvant early stage resectable NSCLC) –Impower030 trial.
- Stereotactic Ablative Radiotherapy for Oligometastatic Non-small Cell Lung Cancer: A Randomised Phase III Trial (SARON study)
- A Multi-Centre Randomised Study of Induction Chemotherapy followed by Capecitabine(+/-nelfinavir) with High or Standard Dose Radiotherapy for Locally Advanced Nonmetastatic Pancreatic Cancer (SCALOP 2 study)
- A Randomised Phase II trial of Standard Versus Dose Escalated Radiotherapy in the Treatment of Pain in Malignant Pleural Mesothelioma (SYSTEM 2 trial)
- A Phase 2 Trial of Pembrolizumab (MK-3475) in Combination with Platinum Doublet Chemotherapy and Radiotherapy for Participants with Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-799)
- A Phase 3 Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) with or without Lenvatinib (E7080/MK-7902) as First-line Intervention in Participants with Metastatic Nonsquamous Non-small Cell Lung Cancer (LEAP-006)
- Adjuvant Durvalumab/placebo following SABR for stage I/II medically inoperable NSCLC (PACIFIC 4 study)
- Adjuvant Durvalumab following Sequential Chemotherapy and Radiotherapy in Patients with Unresecatble Stage III NSCLC (PACIFIC 6 study)
Report an error
Dr. Animesh Saha, Radiation Oncologist Reviews
No feedback available for this Doctor.
Be the first to write a review.
Question & Answers by Dr. Animesh Saha
No Question & Answers by this doctor.
Media from Dr. Animesh Saha
No Videos updated by this doctor.
